Does substance use compromise depression treatment in persons with HIV? Findings from a randomized controlled trial

David J. Grelotti, Gwendolyn P. Hammer, James W. Dilley, Dan H. Karasic, James L. Sorensen, David Bangsberg, Alexander C. Tsai

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Depression and substance use are significant obstacles to effective HIV care. Using data derived from a randomized controlled trial of persons with HIV who are homeless or marginally housed, this study assesses the utility of antidepressant treatment among persons with HIV, depression, and active substance use. Participants were diagnosed with depressive disorders and randomly assigned to receive directly observed therapy with fluoxetine or a referral to community mental health treatment. Assessments, conducted at baseline and every 3 months over a 9-month period, included the Hamilton Rating Scale for Depression, the Beck Depression Inventory II, and self-report of alcohol, crack, cocaine, heroin, or methamphetamine use in the past 90 days. To investigate the effect of antidepressant treatment in the setting of active substance use, the authors fit mixed-effects linear regression models to estimate the effect of directly observed fluoxetine on depressive symptom severity after stratifying by any alcohol use or any illicit drug use. To investigate whether alcohol use or illicit drug use moderated the antidepressant treatment response, the authors examined the interaction terms. The effect of directly observed fluoxetine treatment on depression symptom severity was statistically significant irrespective of alcohol use status. When stratified by illicit drug use status, the effect of directly observed fluoxetine treatment on depression symptom severity was statistically significant only among persons who did not use illicit drugs. The interaction terms were not statistically significant. This study found a benefit of antidepressant treatment in persons with HIV, depression, and alcohol use. In addition, this study found no evidence that either alcohol use or illicit drug use moderates the antidepressant treatment response. Altogether, these findings support the use of antidepressant medication in this population. The public health impact of research in this area is significant given the known adverse effects of depression on HIV-related health outcomes. ClinicalTrials.gov Identifier: NCT00338767.

Original languageEnglish (US)
Pages (from-to)273-279
Number of pages7
JournalAIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV
Volume29
Issue number3
DOIs
StatePublished - Mar 4 2017
Externally publishedYes

Fingerprint

compromise
Randomized Controlled Trials
HIV
Depression
Antidepressive Agents
Street Drugs
human being
alcohol
drug use
Fluoxetine
Alcohols
Therapeutics
Linear Models
Directly Observed Therapy
Crack Cocaine
Methamphetamine
rating scale
interaction
Heroin
Depressive Disorder

Keywords

  • Depression
  • directly observed therapy
  • HIV
  • substance abuse
  • syndemics

ASJC Scopus subject areas

  • Health(social science)
  • Social Psychology
  • Public Health, Environmental and Occupational Health

Cite this

Does substance use compromise depression treatment in persons with HIV? Findings from a randomized controlled trial . / Grelotti, David J.; Hammer, Gwendolyn P.; Dilley, James W.; Karasic, Dan H.; Sorensen, James L.; Bangsberg, David; Tsai, Alexander C.

In: AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, Vol. 29, No. 3, 04.03.2017, p. 273-279.

Research output: Contribution to journalArticle

Grelotti, David J. ; Hammer, Gwendolyn P. ; Dilley, James W. ; Karasic, Dan H. ; Sorensen, James L. ; Bangsberg, David ; Tsai, Alexander C. / Does substance use compromise depression treatment in persons with HIV? Findings from a randomized controlled trial In: AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV. 2017 ; Vol. 29, No. 3. pp. 273-279.
@article{f5aa51b570574e658c5a0d8f6cfd25b3,
title = "Does substance use compromise depression treatment in persons with HIV? Findings from a randomized controlled trial†",
abstract = "Depression and substance use are significant obstacles to effective HIV care. Using data derived from a randomized controlled trial of persons with HIV who are homeless or marginally housed, this study assesses the utility of antidepressant treatment among persons with HIV, depression, and active substance use. Participants were diagnosed with depressive disorders and randomly assigned to receive directly observed therapy with fluoxetine or a referral to community mental health treatment. Assessments, conducted at baseline and every 3 months over a 9-month period, included the Hamilton Rating Scale for Depression, the Beck Depression Inventory II, and self-report of alcohol, crack, cocaine, heroin, or methamphetamine use in the past 90 days. To investigate the effect of antidepressant treatment in the setting of active substance use, the authors fit mixed-effects linear regression models to estimate the effect of directly observed fluoxetine on depressive symptom severity after stratifying by any alcohol use or any illicit drug use. To investigate whether alcohol use or illicit drug use moderated the antidepressant treatment response, the authors examined the interaction terms. The effect of directly observed fluoxetine treatment on depression symptom severity was statistically significant irrespective of alcohol use status. When stratified by illicit drug use status, the effect of directly observed fluoxetine treatment on depression symptom severity was statistically significant only among persons who did not use illicit drugs. The interaction terms were not statistically significant. This study found a benefit of antidepressant treatment in persons with HIV, depression, and alcohol use. In addition, this study found no evidence that either alcohol use or illicit drug use moderates the antidepressant treatment response. Altogether, these findings support the use of antidepressant medication in this population. The public health impact of research in this area is significant given the known adverse effects of depression on HIV-related health outcomes. ClinicalTrials.gov Identifier: NCT00338767.",
keywords = "Depression, directly observed therapy, HIV, substance abuse, syndemics",
author = "Grelotti, {David J.} and Hammer, {Gwendolyn P.} and Dilley, {James W.} and Karasic, {Dan H.} and Sorensen, {James L.} and David Bangsberg and Tsai, {Alexander C.}",
year = "2017",
month = "3",
day = "4",
doi = "10.1080/09540121.2016.1226479",
language = "English (US)",
volume = "29",
pages = "273--279",
journal = "AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV",
issn = "0954-0121",
publisher = "Routledge",
number = "3",

}

TY - JOUR

T1 - Does substance use compromise depression treatment in persons with HIV? Findings from a randomized controlled trial†

AU - Grelotti, David J.

AU - Hammer, Gwendolyn P.

AU - Dilley, James W.

AU - Karasic, Dan H.

AU - Sorensen, James L.

AU - Bangsberg, David

AU - Tsai, Alexander C.

PY - 2017/3/4

Y1 - 2017/3/4

N2 - Depression and substance use are significant obstacles to effective HIV care. Using data derived from a randomized controlled trial of persons with HIV who are homeless or marginally housed, this study assesses the utility of antidepressant treatment among persons with HIV, depression, and active substance use. Participants were diagnosed with depressive disorders and randomly assigned to receive directly observed therapy with fluoxetine or a referral to community mental health treatment. Assessments, conducted at baseline and every 3 months over a 9-month period, included the Hamilton Rating Scale for Depression, the Beck Depression Inventory II, and self-report of alcohol, crack, cocaine, heroin, or methamphetamine use in the past 90 days. To investigate the effect of antidepressant treatment in the setting of active substance use, the authors fit mixed-effects linear regression models to estimate the effect of directly observed fluoxetine on depressive symptom severity after stratifying by any alcohol use or any illicit drug use. To investigate whether alcohol use or illicit drug use moderated the antidepressant treatment response, the authors examined the interaction terms. The effect of directly observed fluoxetine treatment on depression symptom severity was statistically significant irrespective of alcohol use status. When stratified by illicit drug use status, the effect of directly observed fluoxetine treatment on depression symptom severity was statistically significant only among persons who did not use illicit drugs. The interaction terms were not statistically significant. This study found a benefit of antidepressant treatment in persons with HIV, depression, and alcohol use. In addition, this study found no evidence that either alcohol use or illicit drug use moderates the antidepressant treatment response. Altogether, these findings support the use of antidepressant medication in this population. The public health impact of research in this area is significant given the known adverse effects of depression on HIV-related health outcomes. ClinicalTrials.gov Identifier: NCT00338767.

AB - Depression and substance use are significant obstacles to effective HIV care. Using data derived from a randomized controlled trial of persons with HIV who are homeless or marginally housed, this study assesses the utility of antidepressant treatment among persons with HIV, depression, and active substance use. Participants were diagnosed with depressive disorders and randomly assigned to receive directly observed therapy with fluoxetine or a referral to community mental health treatment. Assessments, conducted at baseline and every 3 months over a 9-month period, included the Hamilton Rating Scale for Depression, the Beck Depression Inventory II, and self-report of alcohol, crack, cocaine, heroin, or methamphetamine use in the past 90 days. To investigate the effect of antidepressant treatment in the setting of active substance use, the authors fit mixed-effects linear regression models to estimate the effect of directly observed fluoxetine on depressive symptom severity after stratifying by any alcohol use or any illicit drug use. To investigate whether alcohol use or illicit drug use moderated the antidepressant treatment response, the authors examined the interaction terms. The effect of directly observed fluoxetine treatment on depression symptom severity was statistically significant irrespective of alcohol use status. When stratified by illicit drug use status, the effect of directly observed fluoxetine treatment on depression symptom severity was statistically significant only among persons who did not use illicit drugs. The interaction terms were not statistically significant. This study found a benefit of antidepressant treatment in persons with HIV, depression, and alcohol use. In addition, this study found no evidence that either alcohol use or illicit drug use moderates the antidepressant treatment response. Altogether, these findings support the use of antidepressant medication in this population. The public health impact of research in this area is significant given the known adverse effects of depression on HIV-related health outcomes. ClinicalTrials.gov Identifier: NCT00338767.

KW - Depression

KW - directly observed therapy

KW - HIV

KW - substance abuse

KW - syndemics

UR - http://www.scopus.com/inward/record.url?scp=84984873756&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84984873756&partnerID=8YFLogxK

U2 - 10.1080/09540121.2016.1226479

DO - 10.1080/09540121.2016.1226479

M3 - Article

C2 - 27590273

AN - SCOPUS:84984873756

VL - 29

SP - 273

EP - 279

JO - AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV

JF - AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV

SN - 0954-0121

IS - 3

ER -